Chronic Myelogenous Leukemia News and Research

Latest Chronic Myelogenous Leukemia News and Research

Enhancing the effects of imatinib mesylate used to treat chronic myeloid leukemia

Individuals with chronic myeloid leukemia (CML) are first treated with a drug known as imatinib mesylate.

13 Apr 2009

Data suggesting that omacetaxine can eradicate leukemic stem cells may offer a breakthrough for CML

Data showing the ability of omacetaxine to kill leukemic stem cells in mouse models with drug-resistant chronic myelogenous leukemia (CML) are the subject of an advance online publication in the journal Leukemia, ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today.

29 Mar 2009

When less is more: Brief inhibition of cancer target is effective and less toxic

New research shows that the delicate balance between maximum clinical impact and toxicity may not be quite as fragile as scientists had previously believed.

8 Dec 2008

Researchers discover why Gleevec-type drugs control, but do not eradicate leukemia

Oregon Health & Science University Knight Cancer Institute researchers are closer to understanding why certain chronic myeloid leukemia mutations are not stopped by the revolutionary targeted cancer pill, Gleevec, or similar therapies in that drug family.

8 Dec 2008

Chronic myelogenous leukemia patient survey shows that side effects are a serious issue

Startling findings from a new CML (chronic myelogenous leukemia) patient survey were presented at a satellite meeting of the American Society of Hematology annual meeting, in San Francisco.

8 Dec 2008

Trial shows safety of pre-transplant expansion of umbilical cord blood stem cells

Taking blood stem cells collected from an umbilical cord into the lab and expanding their number before transplanting them to replace a patient's blood supply is as safe as a standard cord blood transplant, researchers reported at the 50th Annual Meeting of the American Society of Hematology.

8 Dec 2008

Trial shows Elitek significantly reduces plasma uric acid levels versus Allopurinol in adults with hematologic cancers at risk for tumor Lysis syndrome

Sanofi-aventis has announced results of a randomized phase III study presented at the 50th Annual Meeting of the American Society of Hematology.

7 Dec 2008

Scientists sequence genome of a cancer patient

For the first time, scientists have decoded the complete DNA of a cancer patient and traced her disease - acute myelogenous leukemia - to its genetic roots.

6 Nov 2008

Gleevec holds potential as first drug to successfully treat neurofibromatosis

Researchers at the Indiana University School of Medicine report that the anti-cancer drug Gleevec holds out promise to become the first effective treatment for neurofibromatosis, a genetic disease that has resisted treatments until now.

30 Oct 2008

Discovery of mechanism and possible drug treatment for growth of nerve tumors in neurofibromatosis

Researchers studying neurofibromatosis type 1 - a rare disease in which tumors grow within nerves - have found that the tumors are triggered by crosstalk between cells in the nerves and cells in the blood.

30 Oct 2008

Cancer requires support from immune system to develop, researchers report

Tumors that grow around nerves in a rare genetic disease need cooperation from cells from the immune system in order to grow, reports a team of scientists, including researchers from UT Southwestern Medical Center.

30 Oct 2008

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).

27 Aug 2008

Researcher develops method for early detection of leukemia relapse

Researchers at the Fred Hutchinson Cancer Research Center have developed a method that allows for the early detection of a common mechanism of resistance on drug treatment for chronic myeloid leukemia.

10 Jul 2008

Arsenic-based agent shown to help eradicate leukemia-initiating cells

In both leukemia and solid tumors, there exists among the multitude of warrior cancer cells a small subgroup that work undercover, patiently lying in wait to launch their attacks. Known as either cancer initiating cells (CICs) or leukemia initiating cells (LICs), these stealth populations are impervious to conventional chemotherapy and undaunted by targeted cancer therapies. When a leukemia patient relapses following a period of remission, it is the LICs that bear responsibility for the disease's reemergence.

12 May 2008

Discovery of small molecule that disrupts Ewing's sarcoma oncogene

Researchers at Georgetown University Medical Center have found a small molecule they say can block the action of the oncogene that causes Ewing's sarcoma, a rare cancer found in children and young adults.

13 Apr 2008

Experimental drug SGX393 offers new approach to help control drug resistance in leukemia

Oregon Health & Science University Cancer Institute researchers have found that an experimental drug known as SGX393 is effective against Gleevec-resistant chronic myeloid leukemia (CML).

25 Mar 2008

Sunitinib may be associated with cardiac toxicity

Another FDA-approved targeted cancer drug, sunitinib (SutentTM, Pfizer), may be associated with cardiac toxicity, report researchers at Children's Hospital Boston, Dana-Farber Cancer Institute (Boston), and Thomas Jefferson University (Philadelphia).

17 Dec 2007

Bosutinib safe, effective for chronic myelogenous leukemia

A new drug for chronic myelogenous leukemia works for patients who have developed resistance to frontline therapy and causes fewer side effects than other medications in its class, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports at the 49th annual meeting of the American Society of Hematology.

12 Dec 2007

Data confirm Dasatinib's effectiveness in resistant chronic myelogenous leukemia

Updated clinical trial results show that the drug dasatinib (Sprycel) continues to be highly effective in patients with chronic myelogenous leukemia who were unable to tolerate Gleevec or who developed resistance to it, reports a team led by researchers at Dana-Farber Cancer Institute.

12 Dec 2007

New drug candidate knocks out resistant form of chronic myeloid leukemia

Oregon Health & Science University Cancer Institute researchers have found a new, experimental drug candidate it to be effective against a highly resistant mutation in chronic myeloid leukemia (CML).

10 Dec 2007

Chronic Myelogenous Leukemia News and Research

Latest Chronic Myelogenous Leukemia News and Research

Enhancing the effects of imatinib mesylate used to treat chronic myeloid leukemia

Data suggesting that omacetaxine can eradicate leukemic stem cells may offer a breakthrough for CML

When less is more: Brief inhibition of cancer target is effective and less toxic

Researchers discover why Gleevec-type drugs control, but do not eradicate leukemia

Chronic myelogenous leukemia patient survey shows that side effects are a serious issue

Trial shows safety of pre-transplant expansion of umbilical cord blood stem cells

Trial shows Elitek significantly reduces plasma uric acid levels versus Allopurinol in adults with hematologic cancers at risk for tumor Lysis syndrome

Scientists sequence genome of a cancer patient

Gleevec holds potential as first drug to successfully treat neurofibromatosis

Discovery of mechanism and possible drug treatment for growth of nerve tumors in neurofibromatosis

Cancer requires support from immune system to develop, researchers report

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Researcher develops method for early detection of leukemia relapse

Arsenic-based agent shown to help eradicate leukemia-initiating cells

Discovery of small molecule that disrupts Ewing's sarcoma oncogene

Experimental drug SGX393 offers new approach to help control drug resistance in leukemia

Sunitinib may be associated with cardiac toxicity

Bosutinib safe, effective for chronic myelogenous leukemia

Data confirm Dasatinib's effectiveness in resistant chronic myelogenous leukemia

New drug candidate knocks out resistant form of chronic myeloid leukemia

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Chronic Myelogenous Leukemia News and Research

Latest Chronic Myelogenous Leukemia News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in